Get to know our clinical trials
Trial of ITF3756 in monotherapy and in combination with a drug against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in patients with advanced solid tumors.
THE OBJECTIVE OF THIS STUDY IS TO ANALYZE THE SAFETY AND TOLERABILITY OF THE STUDY DRUG, ALONE AND IN COMBINATION WITH IPILIMUMAB, AND TO DETERMINE HOW IT IS PROCESSED BY THE BODY.
- PHASE I/IB, OPEN-LABEL, MULTICENTER, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY/TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF ORAL ITF3756 IN MONOTHERAPY AND IN COMBINATION WITH A DRUG AGAINST CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4) IN PATIENTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2022-501089-22-00
- Protocol number: ITF/3756/01
- Promoter: Italfármaco
- Molecule/Drug: ISA101b
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.